SCHEMBL1663638

SCHEMBL1663638

Nc1ccc(N2CCN(C(=O)C3CC3)CC2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.73
GFER P55789 4/20 0.63
CASP6 P55212 1/20 0.63
MAPT P10636 9/20 0.60
ALDH1A1 P00352 6/20 0.60
KMT2A Q03164 4/20 0.60
MEN1 O00255 2/20 0.60
NAMPT P43490 1/20 0.54
ALOX12 P18054 3/20 0.51
LMNA P02545 3/20 0.51
GAA P10253 3/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA9 Q16790 2/20 0.49
KDM4E B2RXH2 2/20 0.49
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3216413 0.94 TDP1 (0.66) TDP1GFERCASP6MAPTALDH1A1
SCHEMBL189163 0.94 ALDH1A1 (0.69) TDP1GFERCASP6MAPTALDH1A1
Hydrochloric Acid SCHEMBL3205122 0.93 TDP1 (0.64) TDP1GFERCASP6MAPTALDH1A1
SCHEMBL8230560 0.90 TDP1 (0.60) TDP1GFERCASP6MAPTALDH1A1
SCHEMBL3209251 0.88 KMT2A (0.59) TDP1GFERCASP6MAPTALDH1A1
SCHEMBL14320485 0.87 TDP1 (0.56) TDP1GFERCASP6MAPTALDH1A1
SCHEMBL520513 0.86 KMT2A (0.58) TDP1GFERCASP6MAPTALDH1A1
SCHEMBL14320635 0.86 TDP1 (0.55) TDP1GFERCASP6MAPTALDH1A1
SCHEMBL14320652 0.84 SMN1; SMN2 (0.57) TDP1MAPTALDH1A1KMT2AMEN1
SCHEMBL3637388 0.84 TDP1 (0.69) TDP1MAPTALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214945-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2025-07-03 US disclosed
US-20250214987-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2025-07-03 US disclosed
EP-4506346-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF Korea University Research and Business Foundation (KR) 2025-02-12 EP disclosed
EP-4501915-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR Korea University Research and Business Foundation (KR) 2025-02-05 EP disclosed
CN-118974021-A Preparation method of thiobenzimidazole derivative and novel intermediate for same 高丽大学校产学协力团 2024-11-15 CN disclosed
CN-118974041-A Thiobenzimidazole derivatives or pharmaceutically acceptable salts thereof and use thereof 高丽大学校产学协力团 2024-11-15 CN disclosed
WO-2023191536-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF 고려대학교 산학협력단 2023-10-05 WO disclosed
WO-2023191536-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF 고려대학교 산학협력단 2023-10-05 WO disclosed
WO-2023191533-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR 고려대학교 산학협력단 2023-10-05 WO disclosed
WO-2023191533-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR 고려대학교 산학협력단 2023-10-05 WO disclosed
EP-2488486-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES Ligand Pharmaceuticals Inc. (US) 2012-08-22 EP disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed
WO-2009145856-A1 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-03 WO disclosed
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-07-02 US disclosed
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-23 US disclosed
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors VIA PHARMACEUTICALS, INC. 2009-04-16 US disclosed
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214987-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR WEE1, WEE2, HADHB TDP1 3237/4885GFER 269/4885CASP6 1453/4885
US-20090093497-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT TDP1 3345/4885GFER 1433/4885CASP6 3996/4885
US-20090170864-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT TDP1 3345/4885GFER 1433/4885CASP6 3996/4885
US-20090099201-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT TDP1 3345/4885GFER 1433/4885CASP6 3996/4885
US-20090105273-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, LCAT TDP1 3345/4885GFER 1433/4885CASP6 3996/4885
US-20250214945-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF TTBK2, TUBB3, TUBB TDP1 1885/4885GFER 4541/4885CASP6 543/4885
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK TDP1 2230/4885GFER 1162/4885CASP6 1437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.